Elevated Lp(a): Guidance for Identifying and Managing Patients

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Lipoprotein(a) (Lp(a)) is a lipoprotein particle independently linked to atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis.
• Elevated Lp(a) is a common genetic dyslipidemia, affecting about 20% of the population, and is associated with increased ASCVD risk.
• Lp(a) is primarily genetic and minimally impacted by lifestyle changes, necessitating targeted therapeutic strategies.

Purpose of the Study:

• To review the role of Lp(a) as a causal risk factor for ASCVD.
• To discuss current therapeutic options and their limitations in managing elevated Lp(a).
• To highlight the potential of novel RNA-based therapies for Lp(a) reduction.

Main Methods:

• Literature review of Lp(a) pathophysiology, epidemiology, and therapeutic approaches.
• Analysis of current lipid-lowering drugs and their effect on Lp(a) levels.
• Examination of investigational RNA-based therapies targeting Lp(a).

Main Results:

• Lp(a) levels ≥125 nmol/L are associated with heightened ASCVD risk, though this threshold lacks universal acceptance.
• Existing therapies like PCSK9 inhibitors offer only moderate Lp(a) reductions and are not specifically indicated for its treatment.
• Four investigational RNA-based agents demonstrate significant Lp(a) reduction (70-100%), with two in outcomes trials.

Conclusions:

• Novel RNA-based therapies represent a promising advancement in managing elevated Lp(a) and reducing ASCVD risk.
• Until these therapies are widely available and proven effective in outcomes trials, intensive management of traditional ASCVD risk factors remains crucial.